Mediclinic International plc (Incorporated in England and Wales) Company Number: 08338604 LSE Share Code: MDC JSE Share Code: MEI NSX Share Code: MEP ISIN: GB00B8HX8Z88 LEI: 2138002S5BSBIZTD5I60 (‘Mediclinic’, or the ‘Company’, or the ‘Group’) 15 December 2022 NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM On 14 December 2022, Gert Hattingh, Chief Governance Officer of Mediclinic, and persons closely associated with him (‘PCA’), Ghwarriebos Investments (Pty) Ltd, sold a total of 100 000 shares in the Company as set out below. The following notification is made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation. 1. Details of persons discharging managerial responsibilities (‘PDMR’) / persons closely associated with them (‘PCA’) a) Name Gert Hattingh 2. Reason for the notification a) Position / status Group Chief Governance Officer – Mediclinic International plc b) Initial notification / Initial notification amendment 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Mediclinic International plc b) LEI 2138002S5BSBIZTD5I60 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Ordinary shares financial instrument Identification Code GB00B8HX8Z88 b) Nature of the Sale of shares transaction c) Price(s) and volume(s) Price(s) Volume(s) ZAR 105.00 23 678 d) Aggregated information Aggregated volume 23 678 Price ZAR 105.00 per share e) Date of the 14 December 2022 transaction f) Place of the JSE transaction 1. Details of persons discharging managerial responsibilities (‘PDMR’) / persons closely associated with them (‘PCA’) a) Name Ghwarriebos Investments (Pty) Ltd 2. Reason for the notification a) Position / status PCA b) Initial notification / Initial notification amendment 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a) Name Mediclinic International plc b) LEI 2138002S5BSBIZTD5I60 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted a) Description of the Ordinary shares financial instrument Identification Code GB00B8HX8Z88 b) Nature of the Sale of shares transaction c) Price(s) and volume(s) Price(s) Volume(s) ZAR 105.00 12 527 ZAR 105.00 44 228 ZAR 105.00 18 238 ZAR 105.01 1 329 d) Aggregated information Aggregated volume 76 322 Price ZAR 105.00 per share e) Date of the 14 December 2022 transaction f) Place of the JSE transaction ABOUT MEDICLINIC INTERNATIONAL PLC Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East. The Group’s core purpose is to enhance the quality of life. Its vision is to be the partner of choice that people trust for all their healthcare needs. Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets. At 30 September 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, three mental health facilities, 21 day case clinics and 23 outpatient clinics. Hirslanden operated 17 hospitals and five day case clinics in Switzerland with around 1 900 inpatient beds; Mediclinic Southern Africa operations included 50 hospitals (three of which in Namibia), five subacute hospitals, three mental health facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and around 8 700 inpatient beds; and Mediclinic Middle East operated seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under management contract Mediclinic Middle East will open a 200-bed hospital in the Kingdom of Saudi Arabia in 2023. The Company’s primary listing is on the London Stock Exchange (‘LSE’) in the United Kingdom, with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia. Mediclinic also holds a 29.7% (2022: 29.9%) interest in Spire Healthcare Group plc, a leading private healthcare group based in the United Kingdom and listed on the LSE. CONTACT INFORMATION Investor queries James Arnold, Head of Investor Relations, Mediclinic International plc +44 (0)20 3786 8181 ir@mediclinic.com Media queries FTI Consulting Ben Atwell/Ciara Martin – UK +44 (0)20 3727 1000 Sherryn Schooling – South Africa +27 (0)21 487 9000 Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom Website: www.mediclinic.com Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Ltd) NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd